<?xml version="1.0" encoding="UTF-8"?>
<OAI-PMH xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.openarchives.org/OAI/2.0/ http://www.openarchives.org/OAI/2.0/OAI-PMH.xsd">
  <responseDate>2024-05-03T02:49:56Z</responseDate>
  <request verb="GetRecord" identifier="oai:pubmedcentral.nih.gov:8105122" metadataPrefix="pmc">https:/www.ncbi.nlm.nih.gov/pmc/oai/oai.cgi</request>
  <GetRecord>
    <record>
      <header>
        <identifier>oai:pubmedcentral.nih.gov:8105122</identifier>
        <datestamp>2021-05-10</datestamp>
        <setSpec>blood</setSpec>
        <setSpec>pmc-open</setSpec>
      </header>
      <metadata>
        <article xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xsi:schemaLocation="https://jats.nlm.nih.gov/ns/archiving/1.3/ https://jats.nlm.nih.gov/archiving/1.3/xsd/JATS-archivearticle1-3.xsd" dtd-version="1.3" xml:lang="en" article-type="brief-report">
          <processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats">
            <restricted-by>pmc</restricted-by>
          </processing-meta>
          <front>
            <journal-meta>
              <journal-id journal-id-type="nlm-ta">Blood</journal-id>
              <journal-id journal-id-type="iso-abbrev">Blood</journal-id>
              <journal-id journal-id-type="hwp">bloodjournal</journal-id>
              <journal-id journal-id-type="publisher-id">Blood</journal-id>
              <journal-title-group>
                <journal-title>Blood</journal-title>
              </journal-title-group>
              <issn pub-type="ppub">0006-4971</issn>
              <issn pub-type="epub">1528-0020</issn>
              <publisher>
                <publisher-name>American Society of Hematology</publisher-name>
                <publisher-loc>Washington, DC</publisher-loc>
              </publisher>
            </journal-meta>
            <article-meta>
              <article-id pub-id-type="accession">PMC8105122</article-id>
              <article-id pub-id-type="pmcid">PMC8105122</article-id>
              <article-id pub-id-type="pmc-uid">8105122</article-id>
              <article-id pub-id-type="pmid">33945605</article-id>
              <article-id pub-id-type="pmid">33945605</article-id>
              <article-id pub-id-type="publisher-id">2021/BLD2021012064</article-id>
              <article-id pub-id-type="doi">10.1182/blood.2021012064</article-id>
              <article-categories>
                <subj-group subj-group-type="category">
                  <subject>Thrombosis and Hemostasis</subject>
                  <subject>Platelets and Thrombopoiesis</subject>
                </subj-group>
                <subj-group subj-group-type="heading">
                  <subject>Thrombosis and Hemostasis</subject>
                </subj-group>
              </article-categories>
              <title-group>
                <article-title>A flow cytometric assay to detect platelet-activating antibodies in VITT after ChAdOx1 nCov-19 vaccination</article-title>
              </title-group>
              <contrib-group>
                <contrib contrib-type="author">
                  <name>
                    <surname>Handtke</surname>
                    <given-names>Stefan</given-names>
                  </name>
                  <xref rid="aff1" ref-type="aff">1</xref>
                  <xref rid="FM1" ref-type="author-notes">*</xref>
                </contrib>
                <contrib contrib-type="author">
                  <contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0002-2723-3299</contrib-id>
                  <name>
                    <surname>Wolff</surname>
                    <given-names>Martina</given-names>
                  </name>
                  <xref rid="aff1" ref-type="aff">1</xref>
                  <xref rid="FM1" ref-type="author-notes">*</xref>
                </contrib>
                <contrib contrib-type="author">
                  <contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0003-1754-1260</contrib-id>
                  <name>
                    <surname>Zaninetti</surname>
                    <given-names>Carlo</given-names>
                  </name>
                  <xref rid="aff1" ref-type="aff">1</xref>
                </contrib>
                <contrib contrib-type="author">
                  <contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0001-5025-7355</contrib-id>
                  <name>
                    <surname>Wesche</surname>
                    <given-names>Jan</given-names>
                  </name>
                  <xref rid="aff1" ref-type="aff">1</xref>
                </contrib>
                <contrib contrib-type="author">
                  <contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0002-6660-9949</contrib-id>
                  <name>
                    <surname>Schönborn</surname>
                    <given-names>Linda</given-names>
                  </name>
                  <xref rid="aff1" ref-type="aff">1</xref>
                </contrib>
                <contrib contrib-type="author">
                  <contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0003-3365-0168</contrib-id>
                  <name>
                    <surname>Aurich</surname>
                    <given-names>Konstanze</given-names>
                  </name>
                  <xref rid="aff1" ref-type="aff">1</xref>
                </contrib>
                <contrib contrib-type="author">
                  <contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0002-3388-8785</contrib-id>
                  <name>
                    <surname>Ulm</surname>
                    <given-names>Lena</given-names>
                  </name>
                  <xref rid="aff2" ref-type="aff">2</xref>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Hübner</surname>
                    <given-names>Nils-Olaf</given-names>
                  </name>
                  <xref rid="aff3" ref-type="aff">3</xref>
                </contrib>
                <contrib contrib-type="author">
                  <contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0002-6391-1341</contrib-id>
                  <name>
                    <surname>Becker</surname>
                    <given-names>Karsten</given-names>
                  </name>
                  <xref rid="aff2" ref-type="aff">2</xref>
                </contrib>
                <contrib contrib-type="author">
                  <contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0003-0177-6508</contrib-id>
                  <name>
                    <surname>Thiele</surname>
                    <given-names>Thomas</given-names>
                  </name>
                  <xref rid="aff1" ref-type="aff">1</xref>
                </contrib>
                <contrib contrib-type="author" corresp="yes">
                  <contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0001-8343-7336</contrib-id>
                  <name>
                    <surname>Greinacher</surname>
                    <given-names>Andreas</given-names>
                  </name>
                  <xref rid="aff1" ref-type="aff">1</xref>
                </contrib>
              </contrib-group>
              <aff id="aff1"><label>1</label>Institute of Immunology and Transfusion Medicine, Department of Transfusion Medicine, </aff>
              <aff id="aff2"><label>2</label>Friedrich Loeffler-Institute of Medical Microbiology, and </aff>
              <aff id="aff3"><label>3</label>Central Unit for Infection Prevention and Control, University Medicine Greifswald, Greifswald, Germany</aff>
              <author-notes>
                <fn id="FM1">
                  <label>*</label>
                  <p>S.H. and M.W. contributed equally to this study.</p>
                </fn>
              </author-notes>
              <pub-date pub-type="ppub">
                <day>01</day>
                <month>7</month>
                <year>2021</year>
              </pub-date>
              <pub-date pub-type="epreprint">
                <day>4</day>
                <month>5</month>
                <year>2021</year>
              </pub-date>
              <pub-date pub-type="pmc-release">
                <day>01</day>
                <month>7</month>
                <year>2021</year>
              </pub-date>
              <!--PMC Release delay is 0 months and 0 days and was based on the <pub-date pub-type="ppub"/>.-->
              <volume>137</volume>
              <issue>26</issue>
              <fpage>3656</fpage>
              <lpage>3659</lpage>
              <history>
                <date date-type="received">
                  <day>8</day>
                  <month>4</month>
                  <year>2021</year>
                </date>
                <date date-type="accepted">
                  <day>3</day>
                  <month>5</month>
                  <year>2021</year>
                </date>
              </history>
              <permissions>
                <copyright-statement>© 2021 by The American Society of Hematology</copyright-statement>
                <copyright-year>2021</copyright-year>
                <license>
                  <license-p>This article is made available via the PMC Open Access Subset for unrestricted reuse and analyses in any form or by any means with acknowledgment of the original source. These permissions are granted for the duration of the World Health Organization (WHO) declaration of COVID-19 as a global pandemic or until permissions are revoked in writing. Upon expiration of these permissions, PMC is granted a perpetual license to make this article available via PMC and Europe PMC, consistent with existing copyright protections.</license-p>
                </license>
              </permissions>
              <self-uri xlink:title="pdf" xlink:href="bloodBLD2021012064.pdf"/>
              <self-uri xlink:role="icon" xlink:href="bloodBLD2021012064_thumb.jpg"/>
              <abstract abstract-type="teaser">
                <p>The detection of vaccine-induced thrombosis and thrombocytopenia (VITT) is an immediate problem in many parts of the world. VITT shows striking similarities to autoimmune heparin-induced thrombocytopenia, and these conditions need to be distinguished. Handtke et al describe a functional whole-blood flow cytometry test for detection of platelet-activating anti-PF4 antibodies that may be specific for VITT.</p>
              </abstract>
              <abstract abstract-type="precis">
                <title>Key Points</title>
                <p>
                  <list list-type="bullet">
                    <list-item>
                      <p>Anti-PF4 antibodies as detected by some PF4/heparin enzyme immunoassays are not specific for VITT.</p>
                    </list-item>
                    <list-item>
                      <p>We provide a functional whole-blood flow cytometry test for detection of platelet-activating anti-PF4 antibodies in VITT.</p>
                    </list-item>
                  </list>
                </p>
              </abstract>
              <abstract abstract-type="graphical">
                <title>Visual Abstract</title>
                <p>
                  <fig position="float" fig-type="featured" id="absf1">
                    <graphic xlink:href="bloodBLD2021012064absf1" position="float"/>
                  </fig>
                </p>
              </abstract>
              <abstract>
                <title>Abstract</title>
                <p>Vaccination is crucial in combatting the severe acute respiratory syndrome coronavirus 2 pandemic. The rare complication of thrombocytopenia and thrombotic complications at unusual sites after ChAdOx1 nCov-19 vaccination is caused by platelet-activating antibodies directed against platelet factor 4 (PF4). We present a widely applicable whole-blood standard flow cytometric assay to identify the pathogenic antibodies associated with vaccine-induced immune-mediated thrombotic thrombocytopenia (VITT) after ChAdOx1 nCov-19 vaccination. This assay will enable rapid diagnosis by many laboratories. This trial was registered at <ext-link xlink:href="http://www.clinicaltrials.gov" ext-link-type="uri">www.clinicaltrials.gov</ext-link> as #NCT04370119.</p>
              </abstract>
              <counts>
                <page-count count="4"/>
              </counts>
            </article-meta>
          </front>
          <body>
            <sec sec-type="intro" id="s1">
              <title>Introduction</title>
              <p>Coronavirus disease 2019 (COVID-19) is caused by the single-stranded RNA virus severe acute respiratory syndrome coronavirus2 (SARS-CoV-2). Currently, 4 different vaccines to prevent symptomatic COVID-19 have been approved by the European Medicines Agency.<xref rid="B1" ref-type="bibr"><sup>1</sup></xref></p>
              <p>Recently, several cases of thrombosis combined with moderate to severe thrombocytopenia were observed in patients vaccinated with the ChAdOx1 nCov-19 (AstraZeneca) vaccine<sup><xref rid="B2" ref-type="bibr">2</xref>‐<xref rid="B5" ref-type="bibr">5</xref></sup> and in patients vaccinated with the Johnson &amp; Johnson vaccine.<xref rid="B6" ref-type="bibr"><sup>6</sup></xref><sup>,</sup><xref rid="B7" ref-type="bibr"><sup>7</sup></xref> We have identified immunoglobulin G antibodies directed against platelet factor 4 (PF4)-activating platelets via FcγRIIa to be the likely cause of vaccine-induced immune-mediated thrombotic thrombocytopenia (VITT).<xref rid="B5" ref-type="bibr"><sup>5</sup></xref> VITT shows striking similarities with autoimmune heparin-induced thrombocytopenia (HIT).<xref rid="B8" ref-type="bibr"><sup>8</sup></xref><sup>,</sup><xref rid="B9" ref-type="bibr"><sup>9</sup></xref> In contrast to HIT, platelet activation in VITT occurs in the presence of PF4 rather than low heparin concentrations. The antibodies associated with recent ChAdOx1 nCov-19 vaccination can be detected by some PF4/heparin enzyme immunoassays (EIAs),<xref rid="B10" ref-type="bibr"><sup>10</sup></xref> which are widely available to diagnose HIT. However, these assays may not be specific for VITT-related antibodies. Not all antibodies binding to PF4/heparin complexes by EIAs are functionally active and others may be typical HIT antibodies. We modified the functional heparin-induced platelet activation test,<xref rid="B11" ref-type="bibr"><sup>11</sup></xref><sup>,</sup><xref rid="B12" ref-type="bibr"><sup>12</sup></xref> a washed platelet assay, to detect vaccine-related antibodies and to differentiate them from HIT antibodies. We have named the modified assay the PF4-induced platelet activation (PIPA) test (for details, see supplemental Methods, available on the <italic toggle="yes">Blood</italic> Web site). As washed platelet assays are restricted to specialized laboratories, we developed a flow cytometric assay using whole blood to detect PF4-dependent platelet-activating antibodies in ChAdOx1 nCov-19–vaccinated patients. By analogy to the washed platelet test, we refer to the modified assay as the PF4-induced flow cytometry–based platelet activation (PIFPA) test.</p>
            </sec>
            <sec id="s2">
              <title>Study design</title>
              <p>For the PIFPA test, citrated whole blood was obtained from healthy donors. Whole blood was supplied with 54 U/mL (final) hirudin (Canyon Pharmaceuticals; if hirudin is not available, then other thrombin inhibitors like <sc>d</sc>-Phe-Pro-Arg-chloromethylketone [PPACK] can be used), and incubated with 0, 5, or 20 µg/mL PF4 (final) for 20 minutes at 37°C. Afterward, heat-inactivated serum (56°C, 30 minutes) from the following donors was added in a whole blood-to-serum ratio of 2:1 and incubated for 20 minutes at 37°C: patients with VITT, asymptomatic vaccinated donors being positive or negative in the anti-PF4/heparin EIA, unvaccinated donors, or patients with HIT. Samples were stained using CD61-phycoerythrin (PE) (clone SZ21; Beckman Coulter) and CD62P-PE-Cy5 (Becton Dickinson) antibodies for 10 minutes (room temperature) in the dark. Stained samples were fixed with 2% paraformaldehyde (Morphisto) for 20 minutes, washed in phosphate-buffered saline (pH 7.4; Pan Biotech), centrifuged (650<italic toggle="yes">g</italic>, 7 minutes, room temperature), and resuspended in 1× fluorescence-activated cell sorter lysing solution (Becton Dickinson). Samples were measured in a Cytomics FC500 flow cytometer (Beckman Coulter). Platelets were positively gated using CD61-PE. Activation was determined by granule release measured using CD62P-PE-Cy5 and given as mean fluorescence intensity (MFI) of the CD62P<sup>+</sup> gated events multiplied by the percentage of gated platelets. Platelet activation for each serum was given as median activation from the 4 whole-blood samples. Further details of thetest method are given in supplemental Methods.</p>
              <p>The use of whole blood and platelets from healthy donors and serum from patients was approved by the Ethics Board at University Medicine Greifswald and was conducted in accordance with the Declaration of Helsinki.</p>
            </sec>
            <sec sec-type="results|discussion" id="s3">
              <title>Results and discussion</title>
              <p>We tested sera from individuals who developed VITT with thrombosis and thrombocytopenia developing 5 to 16 days after vaccination with ChAdOx1 nCov-19 as well as postvaccination serum samples from University Hospital Greifswald health care workers vaccinated with ChAdOx1 nCov-19 (Screening for COVID-19 and Monitoring of Serological Responses to SARS-CoV-2 in Health care Workers [SeCo] study; approved by the Greifswald Ethics Committee, no. BB068/20). Sera were pretested in PF4/heparin EIAs and the functional PIPA test. The flow cytometry–based PIFPA test was performed with 16 VITT samples (14 sera, 2 citrated plasma) and all available EIA<sup>+</sup>/PIPA<sup>−</sup> sera, as well as 10 representative EIA<sup>−</sup>/PIPA<sup>−</sup> sera and 4 sera of patients with HIT who had a positive EIA and positive HIPA result. Cutoff was determined with sera of 13 unvaccinated healthy controls incubated with 5 µg/mL PF4 as mean plus 2× the standard deviation, with samples above the cutoff regarded as positive. The readout of the PIFPA is granule release of platelets measured by CD62P expression. As platelet activation via FcγRIIa shows variability among donors, the PIFPA was always performed with blood from 4 unselected healthy donors, and the median of CD62P expression is shown for each serum in Figure <xref rid="F1" ref-type="fig">1</xref>. Serum from patients with VITT had significantly higher median CD62P expression compared with vaccinated controls without thrombotic complications and without functionally relevant antibodies (EIA<sup>+</sup>/PIPA<sup>−</sup> [<italic toggle="yes">P</italic> = .0009]; EIA<sup>−</sup>/PIPA<sup>−</sup> [<italic toggle="yes">P</italic> = .0003]). However, 3 of the 16 VITT samples remained below the cutoff. By adding 5 µg/mL PF4, all VITT samples tested positive and were clearly distinguished from sera of vaccinated, clinically healthy, asymptomatic individuals with positive EIA but a negative PIPA test (<italic toggle="yes">P</italic> = .0003). All 10 sera that tested EIA<sup>−</sup> and PIPA<sup>−</sup> also tested negative in the PIFPA, and only 1 of the 4 tested HIT sera was slightly above the cutoff when incubated with 20 µg/mL PF4. A low dose of unfractionated heparin (1 U/mL) decreased CD62P expression (<italic toggle="yes">P</italic> = .018) and high doses of heparin further reduced the signal (<italic toggle="yes">P</italic> = .0058). Inhibition of FcγRIIA by the monoclonal antibody IV.3 inhibited platelet activation by 6 tested VITT samples (<italic toggle="yes">P</italic> = .0032), supporting the important role of FcγRIIa in the pathogenesis of this prothrombotic complication of ChAdOx1 nCov-19 vaccination.</p>
              <fig position="float" id="F1">
                <label>Figure 1.</label>
                <caption>
                  <p><bold>Platelet activation in the PIFPA test.</bold> Platelet activation induced by (heat-inactivated; 56°C, 30 minutes) sera and PF4 is shown by CD62P expression and given by the MFI multiplied by percentage of gated events. Data are shown for 16 samples from patients with VITT (14 sera, 2 plasmas), 10 sera from patients after vaccination with positive EIA but negative PIPA result, 10 sera from patients after vaccination with negative EIA and PIPA, and 4 sera from patients with typical HIT. One data point for each serum represents median activation from 4 different whole-blood samples. Cutoff was determined with sera of 13 unvaccinated healthy controls incubated with 5 µg/mL PF4 as the mean plus 2 standard deviations (SD). With the addition of 5 µg/mL PF4, sera from patients with VITT can be readily discriminated from vaccinated donors with no functionally relevant antibodies (<italic toggle="yes">P</italic> &lt; .0003). Statistical significance was calculated by the unpaired Student <italic toggle="yes">t</italic> test. *<italic toggle="yes">P</italic> &lt; .05; **<italic toggle="yes">P</italic> &lt; .01; ***<italic toggle="yes">P</italic> &lt; .001. HIPA, heparin-induced platelet aggregation; UFH, unfractionated heparin.</p>
                </caption>
                <graphic xlink:href="bloodBLD2021012064f1" position="float"/>
              </fig>
              <p>The PIFPA test shows very comparable results to the PIPA test (<xref rid="T1" ref-type="table">Table 1</xref>) and can be applied to confirm or rule out platelet-activating PF4-dependent antibodies, which occur 5 to 16 days after ChAdOx1 nCov-19 vaccination based on available data, without the need for washed platelets. The exact mechanism whereby vaccination with ChAdOx1 nCov-19 is associated with these platelet-activating anti-PF4 antibodies is still unknown. The disorder appears analogous to autoimmune HIT, where antibodies are capable of inducing strong platelet activation despite the absence of heparin, in contrast to typical HIT sera, which require the addition of heparin. Although the PIFPA seems to be specific, we cannot rule out that patients with less severe complications (eg, isolated thrombocytopenia, which have not been identified up to now) may have more weakly reacting antibodies induced by ChAdOx1 nCov-19 for which an additional cofactor might be required (by analogy to HIT, akin to heparin) to produce platelet activation by patient serum. The scientific community should undertake all efforts to screen for such a cofactor (or cofactors). In addition, laboratory tests for antibodies causing HIT using washed platelets are always more sensitive and probably even more specific than assays using whole blood.<xref rid="B13" ref-type="bibr"><sup>13</sup></xref> We therefore recommend that patients with the typical clinical presentation of VITT, but testing negative in the PIFPA, should be further assessed in the PIPA until more information is available.</p>
              <table-wrap position="float" id="T1">
                <label>Table 1.</label>
                <caption>
                  <p>Comparison of the diagnostic tests</p>
                </caption>
                <table frame="hsides" rules="groups">
                  <thead valign="bottom">
                    <tr>
                      <th align="left" rowspan="1" colspan="1"/>
                      <th align="center" rowspan="1" colspan="1">PF4/heparin EIA (OD)</th>
                      <th align="center" rowspan="1" colspan="1">PIPA</th>
                      <th align="center" rowspan="1" colspan="1">PIFPA</th>
                    </tr>
                  </thead>
                  <tbody valign="top">
                    <tr>
                      <td align="left" rowspan="1" colspan="1">
                        <bold>VITT</bold>
                      </td>
                      <td align="center" rowspan="1" colspan="1"/>
                      <td align="center" rowspan="1" colspan="1"/>
                      <td align="center" rowspan="1" colspan="1"/>
                    </tr>
                    <tr>
                      <td align="left" rowspan="1" colspan="1"> 1</td>
                      <td align="center" rowspan="1" colspan="1">+ (3.18)</td>
                      <td align="center" rowspan="1" colspan="1">+</td>
                      <td align="center" rowspan="1" colspan="1">+</td>
                    </tr>
                    <tr>
                      <td align="left" rowspan="1" colspan="1"> 2</td>
                      <td align="center" rowspan="1" colspan="1">+ (3.40)</td>
                      <td align="center" rowspan="1" colspan="1">+</td>
                      <td align="center" rowspan="1" colspan="1">+</td>
                    </tr>
                    <tr>
                      <td align="left" rowspan="1" colspan="1"> 3</td>
                      <td align="center" rowspan="1" colspan="1">+ (3.50)</td>
                      <td align="center" rowspan="1" colspan="1">+</td>
                      <td align="center" rowspan="1" colspan="1">+</td>
                    </tr>
                    <tr>
                      <td align="left" rowspan="1" colspan="1"> 4</td>
                      <td align="center" rowspan="1" colspan="1">+ (3.0)</td>
                      <td align="center" rowspan="1" colspan="1">+</td>
                      <td align="center" rowspan="1" colspan="1">+</td>
                    </tr>
                    <tr>
                      <td align="left" rowspan="1" colspan="1"> 5</td>
                      <td align="center" rowspan="1" colspan="1">+ (3.16)</td>
                      <td align="center" rowspan="1" colspan="1">+</td>
                      <td align="center" rowspan="1" colspan="1">+</td>
                    </tr>
                    <tr>
                      <td align="left" rowspan="1" colspan="1"> 6</td>
                      <td align="center" rowspan="1" colspan="1">+ (2.02)</td>
                      <td align="center" rowspan="1" colspan="1">+</td>
                      <td align="center" rowspan="1" colspan="1">+</td>
                    </tr>
                    <tr>
                      <td align="left" rowspan="1" colspan="1"> 7</td>
                      <td align="center" rowspan="1" colspan="1">+ (3.05)</td>
                      <td align="center" rowspan="1" colspan="1">+</td>
                      <td align="center" rowspan="1" colspan="1">+</td>
                    </tr>
                    <tr>
                      <td align="left" rowspan="1" colspan="1"> 8</td>
                      <td align="center" rowspan="1" colspan="1">+ (3.18)</td>
                      <td align="center" rowspan="1" colspan="1">+</td>
                      <td align="center" rowspan="1" colspan="1">+</td>
                    </tr>
                    <tr>
                      <td align="left" rowspan="1" colspan="1"> 9</td>
                      <td align="center" rowspan="1" colspan="1">+ (3.17)</td>
                      <td align="center" rowspan="1" colspan="1">+</td>
                      <td align="center" rowspan="1" colspan="1">+</td>
                    </tr>
                    <tr>
                      <td align="left" rowspan="1" colspan="1"> 10</td>
                      <td align="center" rowspan="1" colspan="1">+ (3.18)</td>
                      <td align="center" rowspan="1" colspan="1">+</td>
                      <td align="center" rowspan="1" colspan="1">+</td>
                    </tr>
                    <tr>
                      <td align="left" rowspan="1" colspan="1"> 11</td>
                      <td align="center" rowspan="1" colspan="1">+ (3.17)</td>
                      <td align="center" rowspan="1" colspan="1">+</td>
                      <td align="center" rowspan="1" colspan="1">+</td>
                    </tr>
                    <tr>
                      <td align="left" rowspan="1" colspan="1"> 12</td>
                      <td align="center" rowspan="1" colspan="1">+ (3.20)</td>
                      <td align="center" rowspan="1" colspan="1">+</td>
                      <td align="center" rowspan="1" colspan="1">+</td>
                    </tr>
                    <tr>
                      <td align="left" rowspan="1" colspan="1"> 13</td>
                      <td align="center" rowspan="1" colspan="1">+ (3.26)</td>
                      <td align="center" rowspan="1" colspan="1">+</td>
                      <td align="center" rowspan="1" colspan="1">+</td>
                    </tr>
                    <tr>
                      <td align="left" rowspan="1" colspan="1"> 14</td>
                      <td align="center" rowspan="1" colspan="1">+ (3.78)</td>
                      <td align="center" rowspan="1" colspan="1">+</td>
                      <td align="center" rowspan="1" colspan="1">+</td>
                    </tr>
                    <tr>
                      <td align="left" rowspan="1" colspan="1"> 15</td>
                      <td align="center" rowspan="1" colspan="1">+ (3.27)</td>
                      <td align="center" rowspan="1" colspan="1">+</td>
                      <td align="center" rowspan="1" colspan="1">+</td>
                    </tr>
                    <tr>
                      <td align="left" rowspan="1" colspan="1"> 16</td>
                      <td align="center" rowspan="1" colspan="1">+ (2.82)</td>
                      <td align="center" rowspan="1" colspan="1">+</td>
                      <td align="center" rowspan="1" colspan="1">+</td>
                    </tr>
                    <tr>
                      <td align="left" rowspan="1" colspan="1">
                        <bold>Vaccinated asymptomatic</bold>
                      </td>
                      <td align="center" rowspan="1" colspan="1"/>
                      <td align="center" rowspan="1" colspan="1"/>
                      <td align="center" rowspan="1" colspan="1"/>
                    </tr>
                    <tr>
                      <td align="left" rowspan="1" colspan="1"> 01</td>
                      <td align="center" rowspan="1" colspan="1">+ (0.52)</td>
                      <td align="center" rowspan="1" colspan="1">Negative</td>
                      <td align="center" rowspan="1" colspan="1">Negative</td>
                    </tr>
                    <tr>
                      <td align="left" rowspan="1" colspan="1"> 02</td>
                      <td align="center" rowspan="1" colspan="1">+ (0.77)</td>
                      <td align="center" rowspan="1" colspan="1">Negative</td>
                      <td align="center" rowspan="1" colspan="1">Negative</td>
                    </tr>
                    <tr>
                      <td align="left" rowspan="1" colspan="1"> 03</td>
                      <td align="center" rowspan="1" colspan="1">+ (0.89)</td>
                      <td align="center" rowspan="1" colspan="1">Negative</td>
                      <td align="center" rowspan="1" colspan="1">Negative</td>
                    </tr>
                    <tr>
                      <td align="left" rowspan="1" colspan="1"> 04</td>
                      <td align="center" rowspan="1" colspan="1">+ (2.15)</td>
                      <td align="center" rowspan="1" colspan="1">Negative</td>
                      <td align="center" rowspan="1" colspan="1">Negative</td>
                    </tr>
                    <tr>
                      <td align="left" rowspan="1" colspan="1"> 05</td>
                      <td align="center" rowspan="1" colspan="1">+ (0.85)</td>
                      <td align="center" rowspan="1" colspan="1">Negative</td>
                      <td align="center" rowspan="1" colspan="1">Negative</td>
                    </tr>
                    <tr>
                      <td align="left" rowspan="1" colspan="1"> 06</td>
                      <td align="center" rowspan="1" colspan="1">+ (0.60)</td>
                      <td align="center" rowspan="1" colspan="1">Negative</td>
                      <td align="center" rowspan="1" colspan="1">Negative</td>
                    </tr>
                    <tr>
                      <td align="left" rowspan="1" colspan="1"> 07</td>
                      <td align="center" rowspan="1" colspan="1">+ (0.73)</td>
                      <td align="center" rowspan="1" colspan="1">Negative</td>
                      <td align="center" rowspan="1" colspan="1">Negative</td>
                    </tr>
                    <tr>
                      <td align="left" rowspan="1" colspan="1"> 08</td>
                      <td align="center" rowspan="1" colspan="1">+ (0.55)</td>
                      <td align="center" rowspan="1" colspan="1">Negative</td>
                      <td align="center" rowspan="1" colspan="1">Negative</td>
                    </tr>
                    <tr>
                      <td align="left" rowspan="1" colspan="1"> 09</td>
                      <td align="center" rowspan="1" colspan="1">+ (0.67)</td>
                      <td align="center" rowspan="1" colspan="1">Negative</td>
                      <td align="center" rowspan="1" colspan="1">Negative</td>
                    </tr>
                    <tr>
                      <td align="left" rowspan="1" colspan="1"> 10</td>
                      <td align="center" rowspan="1" colspan="1">+ (0.78)</td>
                      <td align="center" rowspan="1" colspan="1">Negative</td>
                      <td align="center" rowspan="1" colspan="1">Negative</td>
                    </tr>
                    <tr>
                      <td align="left" rowspan="1" colspan="1"> 11</td>
                      <td align="center" rowspan="1" colspan="1">Negative (0.15)</td>
                      <td align="center" rowspan="1" colspan="1">Negative</td>
                      <td align="center" rowspan="1" colspan="1">Negative</td>
                    </tr>
                    <tr>
                      <td align="left" rowspan="1" colspan="1"> 12</td>
                      <td align="center" rowspan="1" colspan="1">Negative (0.12)</td>
                      <td align="center" rowspan="1" colspan="1">Negative</td>
                      <td align="center" rowspan="1" colspan="1">Negative</td>
                    </tr>
                    <tr>
                      <td align="left" rowspan="1" colspan="1"> 13</td>
                      <td align="center" rowspan="1" colspan="1">Negative (0.10)</td>
                      <td align="center" rowspan="1" colspan="1">Negative</td>
                      <td align="center" rowspan="1" colspan="1">Negative</td>
                    </tr>
                    <tr>
                      <td align="left" rowspan="1" colspan="1"> 14</td>
                      <td align="center" rowspan="1" colspan="1">Negative (0.06)</td>
                      <td align="center" rowspan="1" colspan="1">Negative</td>
                      <td align="center" rowspan="1" colspan="1">Negative</td>
                    </tr>
                    <tr>
                      <td align="left" rowspan="1" colspan="1"> 15</td>
                      <td align="center" rowspan="1" colspan="1">Negative (0.16)</td>
                      <td align="center" rowspan="1" colspan="1">Negative</td>
                      <td align="center" rowspan="1" colspan="1">Negative</td>
                    </tr>
                    <tr>
                      <td align="left" rowspan="1" colspan="1"> 16</td>
                      <td align="center" rowspan="1" colspan="1">Negative (0.18)</td>
                      <td align="center" rowspan="1" colspan="1">Negative</td>
                      <td align="center" rowspan="1" colspan="1">Negative</td>
                    </tr>
                    <tr>
                      <td align="left" rowspan="1" colspan="1"> 17</td>
                      <td align="center" rowspan="1" colspan="1">Negative (0.21)</td>
                      <td align="center" rowspan="1" colspan="1">Negative</td>
                      <td align="center" rowspan="1" colspan="1">Negative</td>
                    </tr>
                    <tr>
                      <td align="left" rowspan="1" colspan="1"> 18</td>
                      <td align="center" rowspan="1" colspan="1">Negative (0.11)</td>
                      <td align="center" rowspan="1" colspan="1">Negative</td>
                      <td align="center" rowspan="1" colspan="1">Negative</td>
                    </tr>
                    <tr>
                      <td align="left" rowspan="1" colspan="1"> 19</td>
                      <td align="center" rowspan="1" colspan="1">Negative (0.11)</td>
                      <td align="center" rowspan="1" colspan="1">Negative</td>
                      <td align="center" rowspan="1" colspan="1">Negative</td>
                    </tr>
                    <tr>
                      <td align="left" rowspan="1" colspan="1"> 20</td>
                      <td align="center" rowspan="1" colspan="1">Negative (0.12)</td>
                      <td align="center" rowspan="1" colspan="1">Negative</td>
                      <td align="center" rowspan="1" colspan="1">Negative</td>
                    </tr>
                  </tbody>
                </table>
                <table-wrap-foot>
                  <fn id="TF1">
                    <p>Results of the PF4/heparin EIA and the washed platelet PIPA test were compared with the flow cytometry–based PIFPA test. Results of the PF4/heparin EIAs are given in parentheses.</p>
                  </fn>
                  <fn id="TF2">
                    <p>+ indicates that a test was rated positive; OD, optical density.</p>
                  </fn>
                </table-wrap-foot>
              </table-wrap>
              <p>In summary, we present an assay to detect platelet-activating antibodies that seem highly specific for VITT after vaccination with ChAdOx1 nCov-19. The pathogenesis of this severe adverse effect, which threatens the vaccination program in the SARS-CoV-2 pandemic, may be further clarified by rapidly identifying the real incidence of VITT caused by platelet-activating antibodies.</p>
            </sec>
            <sec sec-type="supplementary-material">
              <title>Supplementary Material</title>
              <supplementary-material position="float" content-type="local-data">
                <label>Supplemental File 1</label>
                <media xlink:href="bloodBLD2021012064-suppl1.pdf">
                  <caption>
                    <p>Click here for additional data file.</p>
                  </caption>
                </media>
              </supplementary-material>
              <supplementary-material id="PMC_1" content-type="local-data">
                <caption>
                  <title>View large</title>
                </caption>
                <media mimetype="text" mime-subtype="plain" xlink:href="10.1182-2021012064_bloodbld2021012064absf1.png"/>
              </supplementary-material>
              <supplementary-material id="PMC_2" content-type="local-data">
                <caption>
                  <title>Download slide</title>
                </caption>
                <media mimetype="application" mime-subtype="vnd.ms-powerpoint" xlink:href="10.1182-2021012064_Figure.ppt"/>
              </supplementary-material>
              <supplementary-material id="PMC_3" content-type="local-data">
                <caption>
                  <title>Download PPT</title>
                </caption>
                <media mimetype="application" mime-subtype="vnd.ms-powerpoint" xlink:href="10.1182-2021012064_Figure.ppt"/>
              </supplementary-material>
              <supplementary-material id="PMC_4" content-type="local-data">
                <caption>
                  <title>Supplemental File 1</title>
                </caption>
                <media mimetype="application" mime-subtype="pdf" xlink:href="10.1182-2021012064_bloodbld2021012064-suppl1.pdf"/>
              </supplementary-material>
            </sec>
          </body>
          <back>
            <ack>
              <title>Acknowledgments</title>
              <p>The authors thank Ulrike Strobel, Ricarda Raschke, Ines Warning, Carmen Freyer, Katrin Stein, Jessica Fuhrmann, and Julia Klauke for excellent technical support.</p>
              <p>This work was supported by the Deutsche Forschungsgemeinschaft (DFG; German Research Foundation) project number 374031971–TRR 240.</p>
            </ack>
            <fn-group>
              <fn fn-type="other">
                <p>The data supporting the findings of this study are available from the corresponding author upon reasonable request.</p>
              </fn>
              <fn fn-type="supplementary-material">
                <p>The online version of this article contains a data supplement.</p>
              </fn>
              <fn fn-type="other">
                <p>The publication costs of this article were defrayed in part by page charge payment. Therefore, and solely to indicate this fact, this article is hereby marked “advertisement” in accordance with 18 USC section 1734.</p>
              </fn>
            </fn-group>
            <sec id="s4">
              <title>Authorship</title>
              <p>Contribution: S.H., M.W., C.Z., and J.W. performed the experiments, analyzed the data, and wrote the manuscript; C.Z., L.S., and T.T. coordinated patient samples and the study protocol; L.U., N.-O.H., and K.B. coordinated the SeCo study and provided the samples; K.A. discussed the results and reviewed the manuscript; and A.G. developed the PIPA and the PIFPA concept, supervised the study and experiments, and wrote the manuscript.</p>
              <p>Conflict-of-interest disclosure: A.G. reports grants and nonfinancial support from Aspen, Boehringer Ingelheim, Merck Sharp &amp; Dohme (MSD), Bristol Myers Squibb (BMS), Paringenix, Bayer Healthcare, Gore Inc, Rovi, Sagent, and Biomarin/Prosensa; personal fees from Aspen, Boehringer Ingelheim, MSD, Macopharma, BMS, Chromatec, and Instrumentation Laboratory; and nonfinancial support from Boehringer Ingelheim, Portola, Ergomed, and Gesellschaft für Thrombose und Hämostaseforschung (GTH) eV, outside of the submitted work. T.T. reports personal fees and educational support from BMS, Pfizer, and Chugai Pharma; personal fees from Bayer and Novartis;and educational support from Novo Nordisk and Daiichi Sankyo, outside of the submitted work. The remainingauthors declare no competing financial interests.</p>
              <p>Correspondence: Andreas Greinacher, Institut für Immunologie und Transfusionsmedizin, University Medicine Greifswald, Sauerbruchstr, 17487 Greifswald, Germany; e-mail: <email>andreas.greinacher@med.uni-greifswald.de.</email></p>
            </sec>
            <ref-list>
              <title>REFERENCES</title>
              <ref id="B1">
                <label>1.</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><collab>WHO Ad Hoc Expert Group on the Next Steps for Covid-19 Vaccine Evaluation</collab>; <string-name><surname>Krause</surname><given-names>PR</given-names></string-name>, <string-name><surname>Fleming</surname><given-names>TR</given-names></string-name>, <string-name><surname>Longini</surname><given-names>IM</given-names></string-name>, <etal/></person-group>. <article-title>Placebo-controlled trials of Covid-19 vaccines - why we still need them</article-title>. <source><italic toggle="yes">N Engl J Med.</italic></source><year>2021</year>;<volume>384</volume>(<issue>2</issue>):<fpage>e2</fpage>.<pub-id pub-id-type="pmid">33264543</pub-id></mixed-citation>
              </ref>
              <ref id="B2">
                <label>2.</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Schultz</surname><given-names>NH</given-names></string-name>, <string-name><surname>Sørvoll</surname><given-names>IH</given-names></string-name>, <string-name><surname>Michelsen</surname><given-names>AE</given-names></string-name>, <etal/></person-group>. <article-title>Thrombosis and thrombocytopenia after ChAdOx1 nCoV-19 vaccination</article-title> [published online ahead of print 9 April 2021]. <source><italic toggle="yes">N Engl J Med.</italic></source> doi:10.1056/NEJMoa2104882.</mixed-citation>
              </ref>
              <ref id="B3">
                <label>3.</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Scully</surname><given-names>M</given-names></string-name>, <string-name><surname>Singh</surname><given-names>D</given-names></string-name>, <string-name><surname>Lown</surname><given-names>R</given-names></string-name>, <etal/></person-group>. <article-title>Pathologic antibodies to platelet factor 4 after ChAdOx1 nCoV-19 vaccination</article-title> [published online ahead of print 16 April 2021]. <source><italic toggle="yes">N Engl J Med.</italic></source> doi:10.1056/NEJMoa2105385.</mixed-citation>
              </ref>
              <ref id="B4">
                <label>4.</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Cines</surname><given-names>DB</given-names></string-name>, <string-name><surname>Bussel</surname><given-names>JB.</given-names></string-name></person-group><article-title>SARS-CoV-2 vaccine-induced immune thrombotic thrombocytopenia</article-title> [editorial] [published online ahead of print 16 April 2021]. <source><italic toggle="yes">N Engl J Med.</italic></source> doi:10.1056/NEJMe2106315.</mixed-citation>
              </ref>
              <ref id="B5">
                <label>5.</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Greinacher</surname><given-names>A</given-names></string-name>, <string-name><surname>Thiele</surname><given-names>T</given-names></string-name>, <string-name><surname>Warkentin</surname><given-names>TE</given-names></string-name>, <string-name><surname>Weisser</surname><given-names>K</given-names></string-name>, <string-name><surname>Kyrle</surname><given-names>PA</given-names></string-name>, <string-name><surname>Eichinger</surname><given-names>S.</given-names></string-name></person-group><article-title>Thrombotic thrombocytopenia after ChAdOx1 nCov-19 vaccination</article-title> [published online ahead of print 9 April 2021]. <source><italic toggle="yes">N Engl J Med.</italic></source> doi:10.1056/NEJMoa2104840.</mixed-citation>
              </ref>
              <ref id="B6">
                <label>6.</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Sadoff</surname><given-names>J</given-names></string-name>, <string-name><surname>Davis</surname><given-names>K</given-names></string-name>, <string-name><surname>Douoguih</surname><given-names>M.</given-names></string-name></person-group><article-title>Thrombotic thrombocytopenia after Ad26.COV2.S vaccination - response from the manufacturer</article-title> [published online ahead of print 16 April 2021]. <source><italic toggle="yes">N Engl J Med.</italic></source> doi:10.1056/NEJMc2106075.</mixed-citation>
              </ref>
              <ref id="B7">
                <label>7.</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Muir</surname><given-names>K-L</given-names></string-name>, <string-name><surname>Kallam</surname><given-names>A</given-names></string-name>, <string-name><surname>Koepsell</surname><given-names>SA</given-names></string-name>, <string-name><surname>Gundabolu</surname><given-names>K.</given-names></string-name></person-group><article-title>Thrombotic thrombocytopenia after Ad26.COV2.S vaccination</article-title> [published online ahead of print 16 April 2021]. <source><italic toggle="yes">N Engl J Med.</italic></source> doi:10.1056/NEJMc2105869.</mixed-citation>
              </ref>
              <ref id="B8">
                <label>8.</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Greinacher</surname><given-names>A.</given-names></string-name></person-group><article-title>Clinical Practice. Heparin-induced thrombocytopenia</article-title>. <source><italic toggle="yes">N Engl J Med.</italic></source><year>2015</year>;<volume>373</volume>(<issue>3</issue>):<fpage>252</fpage>-<lpage>261</lpage>.<pub-id pub-id-type="pmid">26176382</pub-id></mixed-citation>
              </ref>
              <ref id="B9">
                <label>9.</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Greinacher</surname><given-names>A</given-names></string-name>, <string-name><surname>Selleng</surname><given-names>K</given-names></string-name>, <string-name><surname>Warkentin</surname><given-names>TE.</given-names></string-name></person-group><article-title>Autoimmune heparin-induced thrombocytopenia</article-title>. <source><italic toggle="yes">J Thromb Haemost.</italic></source><year>2017</year>;<volume>15</volume>(<issue>11</issue>):<fpage>2099</fpage>-<lpage>2114</lpage>.<pub-id pub-id-type="pmid">28846826</pub-id></mixed-citation>
              </ref>
              <ref id="B10">
                <label>10.</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Juhl</surname><given-names>D</given-names></string-name>, <string-name><surname>Eichler</surname><given-names>P</given-names></string-name>, <string-name><surname>Lubenow</surname><given-names>N</given-names></string-name>, <string-name><surname>Strobel</surname><given-names>U</given-names></string-name>, <string-name><surname>Wessel</surname><given-names>A</given-names></string-name>, <string-name><surname>Greinacher</surname><given-names>A.</given-names></string-name></person-group><article-title>Incidence and clinical significance of anti-PF4/heparin antibodies of the IgG, IgM, and IgA class in 755 consecutive patient samples referred for diagnostic testing for heparin-induced thrombocytopenia</article-title>. <source><italic toggle="yes">Eur J Haematol.</italic></source><year>2006</year>;<volume>76</volume>(<issue>5</issue>):<fpage>420</fpage>-<lpage>426</lpage>.<pub-id pub-id-type="pmid">16466367</pub-id></mixed-citation>
              </ref>
              <ref id="B11">
                <label>11.</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Eekels</surname><given-names>JJM</given-names></string-name>, <string-name><surname>Althaus</surname><given-names>K</given-names></string-name>, <string-name><surname>Bakchoul</surname><given-names>T</given-names></string-name>, <etal/></person-group>. <article-title>An international external quality assessment for laboratory diagnosis of heparin-induced thrombocytopenia</article-title>. <source><italic toggle="yes">J Thromb Haemost.</italic></source><year>2019</year>;<volume>17</volume>(<issue>3</issue>):<fpage>525</fpage>-<lpage>531</lpage>.<pub-id pub-id-type="pmid">30640980</pub-id></mixed-citation>
              </ref>
              <ref id="B12">
                <label>12.</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Eichler</surname><given-names>P</given-names></string-name>, <string-name><surname>Budde</surname><given-names>U</given-names></string-name>, <string-name><surname>Haas</surname><given-names>S</given-names></string-name>, <etal/></person-group>. <article-title>First workshop for detection of heparin-induced antibodies: validation of the heparin-induced platelet-activation test (HIPA) in comparison with a PF4/heparin ELISA</article-title>. <source><italic toggle="yes">Thromb Haemost.</italic></source><year>1999</year>;<volume>81</volume>(<issue>4</issue>):<fpage>625</fpage>-<lpage>629</lpage>.<pub-id pub-id-type="pmid">10235451</pub-id></mixed-citation>
              </ref>
              <ref id="B13">
                <label>13.</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Warkentin</surname><given-names>TE.</given-names></string-name></person-group><article-title>Laboratory diagnosis of heparin-induced thrombocytopenia</article-title>. <source><italic toggle="yes">Int J Lab Hematol.</italic></source><year>2019</year>;<volume>41</volume>(<issue>suppl 1</issue>):<fpage>15</fpage>-<lpage>25</lpage>.</mixed-citation>
              </ref>
            </ref-list>
          </back>
        </article>
      </metadata>
    </record>
  </GetRecord>
</OAI-PMH>
